{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T03:54:37Z","timestamp":1783223677431,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.tracli.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T11:17:34Z","timestamp":1678533454000},"page":"307-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advancing blood transfusion safety using molecular detection in the country of Georgia"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1702-2308","authenticated-orcid":false,"given":"Maia","family":"Alkhazashvili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Shadaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinatin","family":"Kuchuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimer","family":"Getia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Turdziladze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige A.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiran","family":"Gamkrelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2023.03.002_b0005","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/trf.15815","article-title":"Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program","volume":"60","author":"Bloch","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0010","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12889-019-6784-3","article-title":"Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination","volume":"19","author":"Hagan","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.tracli.2023.03.002_b0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.puhe.2020.06.024","article-title":"The burden and epidemiology of hepatitis B and hepatitis D in Georgia: findings from the national seroprevalence survey","volume":"185","author":"Kasradze","year":"2020","journal-title":"Public Health"},{"key":"10.1016\/j.tracli.2023.03.002_b0020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.15585\/mmwr.mm6428a2","article-title":"Launch of a Nationwide Hepatitis C Elimination Program-Georgia, April 2015","volume":"64","author":"Mitruka","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.tracli.2023.03.002_b0025","unstructured":"NCDC. Strategic plan for the elimination of Hepatitis C virus in Georgia, 2016-2020. Available from: https:\/\/www.moh.gov.ge\/uploads\/files\/2017\/akordeoni\/failebi\/Georgia_HCV_Elimination_Strategy_2016-2020.pdf."},{"key":"10.1016\/j.tracli.2023.03.002_b0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1023\/A:1015566132757","article-title":"Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donors","volume":"17","author":"Butsashvili","year":"2001","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.tracli.2023.03.002_b0035","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/428578","article-title":"Prospective Evaluation of Community-Acquired Acute-Phase Hepatitis C Virus Infection","volume":"40","author":"Cox","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tracli.2023.03.002_b0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12985-016-0478-6","article-title":"The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia","volume":"13","author":"Tsertsvadze","year":"2016","journal-title":"Virol J"},{"key":"10.1016\/j.tracli.2023.03.002_b0045","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2018-11-833996","article-title":"Prevention of transfusion-transmitted infections","volume":"133","author":"Busch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2023.03.002_b0050","article-title":"Screening Blood Donors for HIV, HCV, and HBV at the American Red Cross: 10-Year Trends in Prevalence, Incidence, and Residual Risk, 2007 to 2016.","volume":"2020","author":"Dodd","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tracli.2023.03.002_b0055","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1537-2995.2005.04390.x","article-title":"Dynamics of viremia in early hepatitis C virus infection","volume":"45","author":"Glynn","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0060","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.tracli.2023.03.002_b0065","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3201\/eid2309.161594","article-title":"Donor evaluation Study, I.I.I.I.C. Use of Blood Donor Screening to Monitor Prevalence of HIV and Hepatitis B and C Viruses, South Africa","volume":"23","author":"Vermeulen","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tracli.2023.03.002_b0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/trf.14959","article-title":"Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes","volume":"59","author":"Vermeulen","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0075","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4254\/wjh.v7.i3.600","article-title":"Occult hepatitis B virus infection and blood transfusion","volume":"7","author":"Seo","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.tracli.2023.03.002_b0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1423-0410.2012.01640.x","article-title":"Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review","volume":"104","author":"Cable","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2023.03.002_b0085","doi-asserted-by":"crossref","first-page":"482","DOI":"10.7326\/M20-0203","article-title":"Blood Transfusion Safety in Low-Resourced Countries: Aspiring to a Higher Standard","volume":"173","author":"Bloch","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tracli.2023.03.002_b0090","unstructured":"Inc, G.D.S. Procleix\u00ae Ultrio Elite Assay. 2011. Available from: https:\/\/ljg1w8gjhvvqr30c.blob.core.windows.net\/storage-web-production\/nybloodcenter\/filer_public\/f8\/ed\/f8edb4dc-c748-4325-8881-595d1487e562\/14-procleix_ultrio_elite_assay_-_gdss-ifu-000006_v50.pdf."},{"key":"10.1016\/j.tracli.2023.03.002_b0095","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1111\/trf.15415","article-title":"Sociodemographic and behavioral characteristics associated with blood donation in the United States: a population-based study","volume":"59","author":"Patel","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0100","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ije\/dyt095","article-title":"Differences between blood donors and a population sample: implications for case-control studies","volume":"42","author":"Golding","year":"2013","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.tracli.2023.03.002_b0105","series-title":"HIV risk and prevention behaviors among People Who Inject Drugs in seven cities of Georgia","author":"Chikovani","year":"2017"},{"key":"10.1016\/j.tracli.2023.03.002_b0110","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1537-2995.2009.02110.x","article-title":"Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa","volume":"49","author":"Vermeulen","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0115","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/hep.21413","article-title":"Blood Transfusion Service Viral Study, G. Characterization of HBV DNA+\/HBsAg- blood donors in Poland identified by triplex NAT","volume":"44","author":"Brojer","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.tracli.2023.03.002_b0120","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3324\/haematol.11224","article-title":"Italian blood donors with anti-HBc and occult hepatitis B virus infection","volume":"92","author":"Manzini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.tracli.2023.03.002_b0125","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1046\/j.1537-2995.2002.00174.x","article-title":"Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population","volume":"42","author":"Dodd","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0130","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/j.1537-2995.2008.01813.x","article-title":"Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey","volume":"48","author":"Velati","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0135","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/trf.14784","article-title":"Blood donor testing for hepatitis B virus in the United States: is there a case for continuation of hepatitis B surface antigen detection?","volume":"58","author":"Dodd","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0140","first-page":"4","article-title":"Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening","volume":"31","author":"Busch","year":"1991","journal-title":"The Transfusion Safety Study Group Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000457965","article-title":"Three-Year Experience in NAT Screening of Blood Donors for Transfusion Transmitted Viruses in Croatia","volume":"44","author":"Safic Stanic","year":"2017","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.tracli.2023.03.002_b0150","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/trf.14949","article-title":"Blood transfusion safety in sub-Saharan Africa: A literature review of changes and challenges in the 21st century","volume":"59","author":"Weimer","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2023.03.002_b0155","doi-asserted-by":"crossref","DOI":"10.1159\/000525480","article-title":"Prevalence of Occult Hepatitis B Virus Infection in Blood Donors with Negative ID-NAT in Switzerland","author":"Zbinden","year":"2022","journal-title":"Transfus Med Hemother"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782023000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782023000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:39:56Z","timestamp":1761129596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782023000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1246782023000381"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2023.03.002","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing blood transfusion safety using molecular detection in the country of Georgia","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}